- Multi-source cases that cannot be narrowed down to a single source are not being reacted to. A discussion is needed to address these cases. A motion was made and seconded to have the committee develop language for a proposal and that proposal be discussed at all regional meetings.

E. Laboratory Committee
- Has resumed monthly calls with several monthly subcommittee calls.

F. Vibrio Research Committee
- Will be developing a request for proposals based on survey conducted by the Research Guidance Committee.

G. Research Guidance Committee
- Surveyed membership for research priorities.
- Committee will use results to prioritize research topics.

H. Training Committee
- Discussed topics for training sections and two presentations were presented at the regional meetings. They were The Regulatory Response to Illness Outbreaks and The Use of CIDT, PFGE and Other Diagnostic Tools in the NSSP.
- The Committee will look at each element of the program and develop training needs for each element. Committee will provide a report to the Executive Board.

VII. OLD BUSINESS

A. US/EU Equivalency Agreement
- Comment for federal register notice closes May 23rd. Supplemental information has been developed by FDA. A link can be provided to anyone that needs it. Once closed, FDA will develop responses. ISSC will provide comments to the notice.
- Trade should be able to resume later this year. Progress will be reported at next Board meeting.
- Export Listing Module will work with ICSSL to automatically send notice to EU for their listing requirements. EU will require a separate list from ICSSL that shows firms shipping from approved growing areas. All exports will require a NOAA certificate.
- Presently, Massachusetts and Washington are the only approved states. Steps for adding other states are in the supplemental document. The agreement is only allowing shellfish from class A areas in EU and approved areas in US. States with *V.v.* Control Plans are excluded initially but may in the future be allowed PHP products.
- ISSC Comments should include:
  a. Conditionally approved areas - Conditionally approved areas meet approved area criteria when in the open status and should be considered acceptable by the EU.
  b. If *V.v.* Control Plan not in place, should be exempt.
  c. PHP products should be allowed because *V.v.* risk is extremely low.
  d. US depurated product should be allowed.
- A motion was made and seconded for ISSC to provide comments to the federal registry notice and suggest that conditionally approved areas be included, depuration be included, that states with *V.v.* plans with product harvested when plans are not in place be included, and PHP product be included. Motion was approved by voice vote by the Board.

B. 2017 Work Plan Evaluation postponed until Executive Session.

C. 2018 Work Plan Approval postponed until Executive Session

D. ISSC Issue I-2016-023 to Conference for Food Protection

- ISSC suggested criticality code be changed from priority foundation to priority violation. CFP agreed. FDA suggested the change would be inconsistent with how codes are included. ISSC supported the FDA position. The CFP Executive Board did not agree and voted to make the change. FDA did not make the change in the latest revision of the Food Code.
- Current focus is on the second recommendation which is for FDA, CFP and ISSC to work together to improve record keeping. A committee made up of members from each conference and FDA will discuss how best to provide information and encourage states to place emphasis on record keeping. The committee is moving forward and the first call will be scheduled soon.

E. Vibrio Research Projects
- Washington and Massachusetts have completed the research that was funded in 2016. Final reports have now been completed and will be posted on the website.
- For future ISSC funded research, a committee will develop a Request for Proposals.

F. Use of CIDT
- Chapter II includes controls for response to *V.p.* illnesses. Response depends on the number of illnesses. In 2017, physicians began using CIDT more frequently. There are less culture confirmed cases as a result. Tests are less expensive. About half of stool samples are positive and only 2/3 of those are being cultured. When cases are now reported, they will not be specific for type of vibrio. Biofire test identifies vibrio but does not speciate. States will not receive the information needed to implement Chapter II requirements.
- Need to put together a technical workgroup and a policy workgroup to address this information and develop recommendations to states regarding this situation.
- A motion was made and seconded to ask the ISSC Executive Office to form a technical workgroup and policy workgroup to provide guidance to states on how to implement Chapter II requirements. Motion was approved by a voice vote by the Board.

VIII. NEW BUSINESS

A. 2018-2019 Committee Rosters and Assignments
- A motion was made and seconded to accept committee rosters as submitted. Motion was approved by a voice vote by the Board.

B. AFDO/FDA Cooperative Agreement
- Not all states applied because some states have a minimum grant limit. Other reasons included confusion due to being combined with the milk program.
- The number of applicants dropped in the second year.
- ISSC has been requested to reapply for the grant in 2019.

C. FDA Response to 2017 Summary of Actions

Overview given of the procedures for reviewing and possible next steps to response.
- Proposal 11-103 Alternative Male-specific Coliphage Meat Standard for Restricted Classification of Growing Areas Impacted by Wastewater Treatment Plant Outfall
  - FDA says the option is to harvest in the area and the MSC requirement becomes mandatory. A motion was made and seconded to refer this proposal back to committee. The Charge will be to clarify how to use MSC not whether to use MSC and to encourage States with depuration program to pilot the use of MSC in classification for depuration harvesting. Motion was approved by a voice vote by the Board.
- Proposal 17-100 Marina Definition

FDA agrees with Conference action to refer to a committee but still believes mooring areas should be assessed. Massachusetts and New York have reviewed draft language for defining mooring areas. This language will be used to begin Committee discussions.

- Proposal 17-217 Removal of Harvester Tags from Shellstock Containers
A motion was made and seconded to send to committee to reconsider proposal and provide an explanation to states. Motion was approved by a voice vote by the Board.
- Proposal 17-305 Responsibilities of the FDA in the Evaluation of States
FDA agrees with having a discussion about FDA evaluation procedures but language for evaluations should not be in the Guide. It should be in the FDA compliance program or in the ISSC Constitution, Bylaws and Procedures.

D. Canadian Norovirus Outbreak
- There have been inquiries from states and industry regarding the handling by Canada of Canadian norovirus outbreak.
- Illnesses were reported in Canada and the US.
Canada closed areas and issued an advisory but did not conduct a recall as they believed product was no longer in the marketplace. Canada did a risk assessment of the growing area. FDA has drafted letter for Canada. Growing area management in Canada is comparable to the US and FDA is concerned with how Canada handles outbreaks. A motion was made and seconded to have Use of Press Committee to evaluate the CORE operating procedures and make recommendations. The motion was approved by a voice vote by the Board. A motion was made and seconded to request that FDA report back to the board following a full assessment of the Canadian Program. The motion was approved by a voice vote of the Board.

E. 2017 NSSP Guide Revision
- The Executive Office will work with FDA and make the Guide available as soon as possible. The process will begin immediately.

F. Proposal 17-212 – FDA requested no action on Proposal 17-212. Following ISSC adoption, FDA realized the requirement is more stringent than other seafood HACCP requirements. A motion was made and seconded that the proposal be sent to Committee. The motion was approved by a voice vote of the Board.

G. Ken Moore advised the Board that a letter was received voicing concern about how Executive Board Elections are conducted. A motion was made and seconded to appoint a committee to review procedures to elect board members. The motion was approved by a voice vote by the Board.

IX. EXECUTIVE DIRECTOR ACTIVITIES

A. The Executive Director recently participated in the following:
1. NoreCORE Final Showcase March 19-21, 2018 in Atlanta, Georgia
2. ISS March 27-29, 2018 in Rehoboth Beach, Delaware
3. PAC RIM April 10-11, 2018 in Blaine, Washington
4. NESSA April 17-18, 2018 in Manchester, New Hampshire
5. GSASSC April 30-May 3, 2018 in Mobile, Alabama

X. EXECUTIVE SESSION

XI. A motion was made and seconded to accept salary adjustments discussed during Executive Session. The motion was approved by a voice vote by the Board.

XII. A motion was made and seconded to adjourn. The motion was approved by a voice vote by the Board.

Meeting adjourned at 11:12 AM.